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Summary
Background Knowledge about the efficacy of behavioural intervention technologies that can be used by cancer 
survivors independently from a health-care provider is scarce. We aimed to assess the efficacy, reach, and usage of 
Oncokompas, a web-based eHealth application that supports survivors in self-management by monitoring health-
related quality of life (HRQOL) and cancer-generic and tumour-specific symptoms and obtaining tailored feedback 
with a personalised overview of supportive care options.
Methods In this non-blinded, randomised, controlled trial, we recruited patients treated at 14 hospitals in the 
Netherlands for head and neck cancer, colorectal cancer, breast cancer, Hodgkin lymphoma, or non-Hodgkin 
lymphoma. Adult survivors (aged ≥18 years) were recruited through the Netherlands Cancer Registry (NCR) and 
invited by their treating physician through the Patient Reported Outcomes Following Initial Treatment and Long term 
Evaluation of Survivorship (PROFILES) registry. Participants were randomly assigned (1:1) by an independent 
researcher to the intervention group (access to Oncokompas) or control group (access to Oncokompas after 6 months), 
by use of block randomisation (block length of 68), stratified by tumour type. The primary outcome was patient 
activation (knowledge, skills, and confidence for self-management), assessed at baseline, post-intervention, and 
3-month and 6-month follow-up. Linear mixed models (intention-to-treat) were used to assess group differences over 
time from baseline to 6-month follow-up. The trial is registered in the Netherlands Trial Register, NTR5774 and is 
completed.
Findings Between Oct 12, 2016, and May 24, 2018, 625 (21%) of 2953 survivors assessed for eligibility were recruited 
and randomly assigned to the intervention (320) or control group (305). Median follow-up was 6 months (IQR 6−6). 
Patient activation was not significantly different between intervention and control group over time (difference at 
6-month follow-up 1·7 [95% CI −0·8–4·1], p=0·41).
Interpretation Oncokompas did not improve the amount of knowledge, skills, and confidence for self-management in 
cancer survivors. This study contributes to the evidence for the development of tailored strategies for development 
and implementation of behavioural intervention technologies among cancer survivors.
Funding Dutch Cancer Society (KWF Kankerbestrijding).
Copyright © 2019 Elsevier Ltd. All rights reserved.
Introduction
In cancer survivorship care, government policy statements 
and national guidelines reflect scientific and societal 
support for an integrated approach to supportive care, 
which includes rehabilitation, psychosocial care, and 
lifestyle interventions.1,2 For optimal referral to supportive 
care, there are guidelines on patient-reported outcome 
measures in clinical practice. Behavioural intervention 
technologies are used to collect and pro cess patient-
reported outcome measure data. Most are adjunctive or 
guided behavioural intervention tech nologies, and a 
health-care provider is needed to discuss the results and 
the supportive care options that best fit the patient’s 
needs.3 Reviews showed that online self-management 
interventions can have positive effects on health-related 
quality of life (HRQOL) and symptom burden in patients 
with cancer.3–5 Randomised controlled trials mostly 
targeted cancer survivors during or shortly after treat-
ment, included cancer-generic symptoms and less often 
tumour-specific symptoms, and most interventions 
comprised adjunctive or guided behavi oural intervention 
technologies.3–7 Knowledge about the efficacy of a fully 
automated behavioural intervention technology that 
can be used by cancer survivors independently from a 
health-care provider is scarce. Therefore, we developed 
Oncokompas, which supports cancer survivors in 
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self-management, by monitoring symptoms (cancer-
generic and tumour-specific) and HRQOL, providing 
feedback and infor mation, and a personalised overview of 
supportive care options, with the aim to reduce symptom 
burden and improve HRQOL.8–13 Oncokompas follows a 
tailored care approach: survivors receive personalised 
information on their scores; survivors with minor 
problems are informed about self-help interventions, and 
survivors with major problems about professional care.
Oncokompas was developed according to a participatory 
design approach, including survivors, health-care pro-
fessionals, managerial staff, and insurance com panies. 
Qualitative studies suggested that there was a need 
for Oncokompas among survivors and health-care 
providers.8,10 Quantitative feasibility studies showed that 
the proportion of participants who used Oncokompas 
was high (64%), that survivors and health-care 
professionals were satisfied with the application,9,11 and 
that it might lead to improved knowledge, skills and 
confidence for self-management.11 A national pilot study 
on the adoption and implementation of Oncokompas in 
65 hospitals showed that the adoption rate was 31%, and 
within these adopting hospitals, implementation rate 
was 71%.12 One of the reasons given for not adopting or 
implementing Oncokompas was that no information 
was available on efficacy.
The aim of the present study was to evaluate the reach, 
usage as intended, and efficacy of Oncokompas to 
improve knowledge, skills, and confidence for self-
management among survivors of head and neck cancer, 
colorectal cancer, breast cancer, Hodgkin lymphoma, or 
non-Hodgkin lymphoma. We also explored effects on 
HRQOL and tumour-specific symptoms, mental adjust-
ment to cancer, supportive care needs, self-efficacy, 
personal control, and patient–physician interaction.
Methods
Study design and participants
In this randomised controlled trial, cancer survivors were 
recruited through the Netherlands Cancer Registry, and 
invited by their (former) treating physician at 14 hospitals 
through the Patient Reported Outcomes Following Initial 
Treatment and Long term Evaluation of Survivorship 
(PROFILES) registry (appendix p2).14 Inclusion criteria 
were survivors diagnosed with head and neck cancer, 
colorectal cancer, breast cancer, Hodgkin lymphoma, or 
non-Hodgkin lymphoma. These tumour types were 
chosen to ensure variability regarding age, sex, tumour 
type prevalence, solid and non-solid tumour types, 
cancer-related and treatment-related symptoms, and the 
need for various types of supportive care. Patients had to 
be aged at least 18 years and be 3 months to 5 years after 
treatment with curative intent (all treatment modalities). 
Survivors on endocrine or immunotherapy, or a wait-
and-see regimen were included 3 months after previous 
treatment or diagnosis. Exclusion criteria were no access 
Research in context
Evidence before this study
We searched for systematic reviews and meta-analyses in 
PubMed and via reference lists of papers published, from 
July 1, 2014, to July 1, 2019 with the search terms “cancer 
survivors”, “patient reported outcome”, “symptom 
monitoring”, “self-management interventions”, and “eHealth”. 
Results from reviews on web-based symptom monitoring as 
well as on self-management interventions suggest that these 
can be effective to reduce symptom burden and improve 
health-related quality of life (HRQOL). However, most of the 
previous studies targeted patients during or shortly after 
treatment, included most often cancer-generic symptoms but 
less often tumour-specific symptoms, and most interventions 
comprised behavioural intervention technologies that were 
part of routine care, as adjunctive or guided behavioural 
intervention technologies. Knowledge on the reach and efficacy 
of a fully automated behavioural intervention technology that 
can be used by survivors independently from a health-care 
provider is scarce. Therefore, we developed the eHealth 
self-management application Oncokompas, which aims to 
support survivors in self-management by monitoring 
cancer-generic and tumour-specific symptoms, providing 
feedback and information on their scores, as well as a 
personalised overview of supportive care options, with the aim 
to reduce symptom burden and improve HRQOL. According to 
participatory design principles, several studies were done to 
investigate the needs of patients and health-care professionals, 
and the feasibility of Oncokompas.
Added value of this study
This randomised controlled trial showed that Oncokompas did 
not significantly improve knowledge, skills, or confidence for 
self-management or other secondary outcome measures, such 
as supportive care needs, but seems to reduce symptom burden 
and improve HRQOL. These findings contribute to developing 
tailored strategies for development and implementation of 
eHealth applications among cancer survivors.
Implications of all the available evidence
Considering all available evidence, fully automated 
behavioural intervention technologies such as Oncokompas 
could potentially facilitate sustainability of long-term cancer 
survivorship care; however, this trial did not find a difference 
in the primary endpoint of patient activation. Further research 
is needed to identify which components of Oncokompas are 
fundamental for improving HRQOL and symptoms and 
whether Oncokompas is cost-effective compared with usual 
survivorship care. Also, further qualitative research and 
process evaluations are needed to guide scaling up of 
behavioural intervention technologies such as Oncokompas, 
which remains a challenge.
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to the internet or no email address, severe cognitive 
impairment, insufficient mastery of the Dutch language, 
physical inability to complete a questionnaire, and male 
breast cancer survivors.13
To establish the reach of Oncokompas (defined as the 
proportion of eligible survivors and the proportion of 
participating survivors), survivors were first invited in an 
online or paper-and-pencil survey on supportive care. 
Eligible survivors were invited to participate in the 
randomised controlled trial. After the first recruitment 
phase with sufficient respondents to evaluate the reach, 
survivors were invited directly to participate in the 
randomised controlled trial, to speed up recruitment. We 
needed at least 200 participants to do multivariable 
logistic regression analyses on eligbility and participation. 
This deviated from the protocol, which specified that all 
participants in the randomised controlled trial were 
recruited via the survey on supportive care.13
Participants in the randomised controlled trial provided 
informed consent online; for the survey on supportive 
care, there was the option to send the informed consent 
form by post. The study protocol was approved by the 
Medical Ethics Committee of VU University Medical 
Center (2015.523). The protocol has previously been 
published.13
Randomisation and masking
Participants were randomly assigned (1:1) to the 
intervention group (direct access to Oncokompas) or 
wait-list control group (access to Oncokompas after 
6 months) using block randomisation. Randomisation 
was done by a researcher not involved in the study; the 
allocation sequence was extracted from a database with 
all included participant numbers. Randomisation was 
stratified by tumour type, and blocks with a length of 
68 were used. Assignment to the trial group and 
invitation to the intervention was done by a researcher 
(AvdH). Owing to the nature of the intervention, 
participants could not be masked.
Procedures
The web-based eHealth application Oncokompas aims 
to support cancer survivors in self-management by 
monitoring cancer-generic and tumour-specific symp-
toms and HRQOL, providing feedback and information 
on the scores and a personalised overview of supportive 
care options, with the aim to reduce symptom burden 
and improve HRQOL. According to the biopsychosocial 
model,29 the content of Oncokompas includes various 
topics in five generic HRQOL domains: physical 
functioning, psychological functioning, social function-
ing, lifestyle, and existential issues, and included topics 
in tumour-specific modules (appendix p 1). Following the 
chronic care self-management model,30 Oncokompas 
consists of three components: Measure, Learn, and Act. 
It is expected that users improve their knowledge, skills, 
and confidence for self-management if they use at least 
the two components Measure and Learn (so, Measure 
and Learn or Measure, Learn, and Act, for at least one 
topic). Cancer survivors are informed in Oncokompas 
that can they can choose which topics they want to 
address. Automatically generated reminders are sent 
every 3 months, to encourage repeated use of 
Oncokompas. A helpdesk is available, which users can 
contact via email or telephone.
In the Measure component, survivors can complete 
patient-reported outcome measures on the topics of 
choice. Per topic, a patient-reported outcome measure 
was selected by the project team in collaboration with 
experts, on the basis of Dutch guidelines and literature 
searches, for instance, subscales of the European 
Organisation for Research and Treatment of Cancer 
(EORTC). Data from the Measure component are 
processed in real-time and linked to tailored feedback to 
the survivor in the Learn component. All algorithm 
calculations are based on available cut-off scores, or are 
defined on the basis of Dutch practice guidelines, 
literature searches or consensus by teams of experts. In 
the Learn component, feedback is provided by means of 
a 3-colour system: green (no elevated wellbeing risks), 
orange (elevated wellbeing risks), and red (seriously 
elevated wellbeing risks). Survivors receive personalised 
information on the outcomes (eg, on the topic depression, 
information is provided on symptoms of depression and 
the proportion of survivors who suffer from depressive 
symptoms). Special attention is paid to evidence-based 
associations between outcomes. For example, feedback 
on the association between depression and fatigue is 
provided, if a survivor has an orange or a red score on 
depression as well as on fatigue. The feedback in the 
Learn component concludes with tailored self-care 
advice, with tips and tools. In the Act component, 
survivors are provided with personalised supportive care 
options, on the basis of their patient-reported outcome 
measure scores and expressed preferences (eg, preference 
for individual therapy vs group therapy). If a survivor has 
elevated wellbeing risks (orange score), the feedback 
includes suggestions for self-help interventions. If a 
survivor has seriously elevated wellbeing risks, the 
feedback includes advice to contact a medical specialist 
or their general practitioner. This advice is evidence-
based (when evidence was found in literature), based on 
guidelines, or consensus recommendations from expert 
meetings.
Cancer survivors obtain access to Oncokompas via their 
health-care provider who invites the survivor by 
submitting an online form within Oncokompas including 
name, email address, date of birth, treatment phase 
(before–during–after treatment), and postal code. The 
Oncokompas system then automatically sends an 
activation link to the email address of the survivor. 
Verification of identity happens in real-time by asking 
survivors to re-enter date of birth, after which registration 
is completed and they can start the Measure component 
See Online for appendix
For more on EORTC see 
https://qol.eortc.org/
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as described. Oncokompas is considered to be a medical 
device and is in compliance with Dutch and European 
laws and regulations (Medical Device Directive and 
General Data Protection Regulation). All data are stored 
safely and encrypted by a hosting company, which is 
certified for Dutch NEN7510 norms for information 
security in health care. Code-sharing of the algorithms in 
Oncokompas is possible after signing a bilateral confi-
dentially agreement. Outcome measures were collected at 
time of inclusion (baseline), 1 week post-intervention, 
and after 3 months and 6 months of follow-up. In the 
intervention group, the first post-intervention question-
naire was sent 1 week after the use of Oncokompas, but 
not later than 2 weeks after randomisation. In case a 
participant did not use Oncokompas, the first post-
intervention questionnaire was sent 2 weeks after 
randomisation. In the control group, the first post-
intervention questionnaire was sent 2 weeks after 
randomisation.
 The Patient Activation Measure is a patient-reported 
outcome measure that measures a patient’s amount of 
knowledge, skills, and confidence for self-management. 
The score ranges from 0 to 100 (higher score indicates 
higher patient activation).15 The patient activation 
measure is a 13-item patient-reported outcome measure 
in which the respondents are asked to report their level 
of agreement with various statements on a 4-point Likert 
scale (ie, strongly disagree, disagree, agree, strongly 
agree) or to indicate that the item is not applicable. 
Statements are for instance, “Taking an active role in my 
own health care is the most important factor in 
determining my health and ability to function”, “I am 
confident I can tell my health-care provider concerns I 
have even when he or she does not ask”, and “I 
understand the nature and causes of my health 
condition(s)”. The summary score of the EORTC 
QLQ-C30 is based on five functional scales (physical, 
cognitive, emotional, social, and role functioning), three 
symptom scales (fatigue, nausea–vomiting, and pain) 
and five single items (dyspnoea, insomnia, appetite loss, 
constipation, and diarrhoea). The summary score ranges 
from 0 to 100 (higher score representing better HRQOL).16 
The mental adjustment to cancer scale comprises two 
summary subscales: summary positive adjustment 
(scores range 17–68; higher score indicating more 
positive adjustment) and summary negative adjustment 
(score range 16–64; higher score indicating more negative 
adjustment).17 The Supportive Care Needs Survey Short 
Form 34 contains 4 domains: physical and daily living, 
psychological, sexuality, and health system, information, 
and patient support. Scores range from 0 to 100 (higher 
score reflecting a higher need).18 The General Self-Efficacy 
scale assesses optimistic self-beliefs regarding coping 
with difficult demands in life; its total score ranges from 
10 to 40 (higher score reflecting higher self-efficacy).19 
The Pearlin & Schooler Mastery Scale measures global 
sense of personal control; its score ranges from 7 to 35 
(a higher score reflecting greater mastery).20 The 
Perceived Efficacy Patient-Physician Interactions scale 
measures patients’ confidence in interacting with their 
care provider; its score ranges from 5 to 25 (a higher 
score reflecting better confidence).21 Head and neck 
cancer symptoms were measured by means of the 
EORTC QLQ-H&N43;22 colorectal cancer symptoms were 
measured by means of the EORTC QLQ-CR29;23 breast 
cancer symptoms were measured by means of the 
EORTC QLQ-BR23;24 and Hodgkin lymphoma and non-
Hodgkin lymphoma symptoms were measured by 
means of the EORTC-QLQ-NHL-HG29 (high grade non-
Hodgkin lymphoma), EORTC QLQ-NHL-LG20 (low 
grade non-Hodgkin lym phoma), and EORTC QLQ-HL27 
(Hodgkin lymphoma).25 All EORTC scales and single 
items scores range from 0 to 100 (higher scores on 
symptom scales indicating higher burden of symptoms, 
and higher scores on functional scales indicating better 
functioning). Socio demographic factors and clinical 
characteristics were measured with a study-specific 
questionnaire (marital status, education, treat ment 
modality, comor bidities, employment status), or extracted 
from the NCR (age, sex, tumour type, tumour stage, time 
since cancer diagnosis). The Functional, Communicative 
and Critical Health Literacy scale measures health 
literacy; its score ranges from 1 to 4 (a higher score 
reflecting better health literacy).26 The Multidimensional 
Health Locus of Control scale measures three domains 
(subscales) of health locus of control: internal health 
locus of control, powerful others, and chance. Subscale 
scores range from 6 to 36 points (a higher score indicating 
stronger self-perceived influence of that domain).27 The 
eHealth Impact Questionnaire (Part 1) measures 
attitudes towards online health information, comfort 
with sharing health experiences online, and usefulness 
of sharing health experiences online. Subscale scores 
range from 0 to 100.28
Outcomes
The primary outcome was patient activation (knowledge, 
skills and confidence for self-management) according to 
the patient activation measure (range 0–100 [highest 
scores show highest activation]).15 Secondary outcomes 
were HRQOL (including tumour-specific symptoms 
within the tumour groups), mental adjustment to cancer, 
supportive care needs, self-efficacy, personal control, and 
perceived efficacy in patient–physician interaction. Reach 
(an exploratory outcome) was defined as the proportion 
of eligible survivors and proportion of participating 
survivors. Cost-utility outcomes was also prespecified as 
a secondary outcome and will be reported elsewhere.
Statistical analysis
The hypothesis was that Oncokompas supports cancer 
survivors to improve their knowledge, skills, and 
confidence for self-management (patient activation). The 
study was powered to detect a clinically meaningful 
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difference of 0·5 standard units for the intervention 
group versus control group on the primary outcome 
measure (patient activation measure score) per tumour 
type (head and neck cancer, colorectal cancer, breast 
cancer, Hodgkin lymphoma, or non-Hodgkin lymphoma) 
at 6-months follow-up. With a power of 80% and α of 
0·05, a minimum of 51 participants were needed per 
study arm. Anticipating drop-out of 25%, we aimed to 
include 136 participants for each tumour type divided 
into two arms, and in total 544 participants.
Descriptive statistics were generated for socio-
demographic and clinical characteristics and outcome 
measures. χ² tests, independent samples t tests or 
Mann-Whitney U tests were used to analyse whether 
randomisation resulted in similar patient groups as 
prespecified in the study protocol. p<0·05 was deemed to 
be significant.
The proportion of eligible survivors was calculated as 
the number of eligible respondents (access to the internet 
and an email address) divided by the number of 
respondents of the survey on supportive care. The 
proportion of participating survivors was calculated as 
the number of participants who were randomly assigned, 
divided by the number of eligible respondents.
Multivariable logistic regression analyses were done to 
identify which sociodemographic, clinical, and psycho-
social factors were associated with eligibility and 
participation in Oncokompas (reach). In case there were 
missing questions, the scoring manual of the 
questionnaire was followed on how to deal with missing 
items.
Linear mixed models were used to compare 
longitudinal changes in primary and secondary outcomes 
between both groups over time, according to the 
intention-to-treat principles. The models included fixed 
effects for group, time, and the interaction for 
time*group, and a random intercept for subject. For the 
primary outcome, linear mixed models analyses were 
also stratified per tumour type.
Post-hoc analyses were done among outcomes with a 
significantly different course between intervention and 
control group over time, to assess at which follow-up 
measurements the groups were different, with inde-
pendent samples t tests. Cohen’s d was calculated 
(effect size) by computing the difference between mean 
score of the intervention group minus the mean score 
of the control group divided by the pooled standard 
deviation. The magnitude of the effect size was 
classified as large (≥0·80), moderate (0·50–0·79), or 
small (<0·50). We also assessed engagement post-hoc, 
which was defined as the proportion of survivors in the 
intervention group who used Oncokompas as intended. 
For associations with eligibility, participation and 
usage, sociodemographic (sex, age, education, marital 
status, employment status), clinical (tumour type, 
stage, treatment, time since diagnosis, comorbidity), 
and psychosocial factors (outcomes on efficacy, locus of 
2953 patients accessed for eligibility
625 randomly assigned
2328 excluded
 211 no internet or email, or both
 243 not interested in participation
   1874 no response
320 allocated to intervention group
 318 received allocated intervention
 2 did not receive allocated intervention
 1 too burdensome 
 1 died
264 1-weeks’ follow-up
 2 died 
 36 no response
231 3-month follow-up
 37 no response
225 6-month follow-up 
 31 no response
320 included in the intention-to-treat analysis
305 allocated to control group
 304 received allocated intervention
 1 did not receive allocated intervention
 1 too burdensome 
13 withdrew from study
 2 poor health condition 
 3 lacking internet skills 
 1 personal circumstances 
 4 questions too burdensome or time
 consuming 
 1 questions not applicable 
 2 unknown
275 1-weeks’ follow-up
 1 died 
 15 no response
261 3-month follow-up
 17 no response
251 6-month follow-up 
 1 died
 15 no response
305 included in the intention-to-treat analysis
16 withdrew from study
 3 poor health condition 
 2 lacking internet skills 
 1 personal circumstances 
 7 questions too burdensome or time 
  consuming 
 2 questions not applicable 
 1 unknown
12 withdrew from study
 1 poor health condition 
 4 lacking internet skills 
 7 questions too burdensome or time
 consuming 
32 withdrew from study
 4 poor health condition 
 3 lacking internet skills 
 5 personal circumstances 
 12 questions too burdensome or time 
  consuming 
 7 questions not applicable 
 1 unknown
11 withdrew from study
 2 poor health condition 
 1 lacking internet skills 
 2 personal circumstances
 3 questions too burdensome or time 
 consuming 
 2 questions not applicable 
 1 unknown 
12 withdrew from study
 3 poor health condition 
 2 lacking internet skills 
 3 personal circumstances 
 4 questions too burdensome or time 
 consuming
Figure 1: Trial profile
Randomisation and sending the invitation for Oncokompas to participants in the intervention group were on the 
same day. The follow-up measurements were 3 and 6 months after randomisation, for both groups. In the 
intervention group, first post-intervention questionnaire was sent 1 week after the use of Oncokompas, and in the 
control group, first post-intervention questionnaire was sent 2 weeks after randomisation.
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control, and health literacy) were taken into account, 
and for the associations with participation and 
engagement also internet-related factors (hours of 
internet use, cancer-related internet searching, attitude 
towards eHealth [participation only]). The research 
committee of the Amsterdam Public Health research 
institute audited the study. First, univariable logistic 
regression analyses were done. Due to the large number 
of possible covariates, variables with a p-value of <0·25 
in the univariable logistic regression analyses were 
selected. With those variables, a multivariable backward 
selection procedure was performed to identify factors 
that were independently associated with eligibility for, 
participation in, and usage of Oncokompas.
All analyses were two-sided and done by means of 
SPSS (version 25). The trial is registered with the 
Netherlands Trial Register, NTR5774.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all of the data and the final responsibility to submit for 
publication.
Results
2953 cancer survivors were invited to participate 
between Oct 12, 2016, and May 24, 2018. 625 (21%) of 
these survivors consented to participate, completed the 
baseline assessment, and were randomly allocated to 
the intervention (n=320) or control (n=305) group 
(figure 1, table 1). Overall, 56% of participants had 
tumour stage I or II, 76% had no or only one comorbidity, 
and 57% had survived for more than 2 years after 
diagnosis (table 1). Baseline scores were in the top 
10−30% of the score for HRQOL, negative adjustment 
to cancer, unmet supportive care needs, self-efficacy, 
and patient-physician interaction (table 2), as well as on 
most of the tumour-specific symptoms (table 3). 
60 (19%) of 320 participants in the intervention group 
and 36 participants (12%) of 305 patients in the control 
group withdrew from the study (figure 1). The median 
follow-up period was 6 months (IQR 6−6).
The results of the linear mixed-model analyses are 
shown in table 2. The course of patient activation 
(primary endpoint) was not significantly different 
between the intervention group and the control group 
over time (difference at 6-months follow-up 1·7 [95% CI 
−0·8 to 4·1; p=0·41]; table 2), nor in the stratified analyses 
per tumour type (appendix p 3). The course of HRQOL 
summary score was significantly different between the 
intervention group and control group over time (p=0·048; 
difference at 6 months follow-up 2·3 [95% CI 0·0–4·5]; 
table 2, figure 2A). There were no significant differences 
between intervention and control group on the course of 
mental adjustment to cancer, supportive care needs, self-
efficacy, personal control, or patient-physician interaction 
over time (table 2). Effects of Oncokompas on various 
tumour-specific symptoms are shown in table 3.
In head and neck cancer survivors, the course of the 
symptoms pain in the mouth, social eating, swallowing, 
coughing, and trismus were significantly different 
between the intervention group and control group over 
time. In colorectal cancer survivors, the course of the 
symptom weight was significantly different between the 
inter vention group and control group over time. In high 
grade non-Hodgkin lymphoma survivors, the course of 
the symptom emotional impacts was significantly 
Intervention (n=320) Control (n=305)
Age, years 65 (56–71) 65 (57–71)
Women 158 (49%) 158 (52%)
Men 162 (51%) 147 (48%)
Education level
Low 111 (35%) 117 (39%)
Medium 105 (33%) 85 (28%)
High 103 (32%) 100 (33%)
Missing 1 (<1%) 3 (1%)
Health literacy 3·2 (0·5) 3·2 (0·5)
Marital status, partner 265 (83%) 269 (88%)
Employment status, 
employed
122 (38%) 99 (33%)
Tumour type
Breast cancer 66 (21%) 72 (24%)
Colorectal cancer 80 (25%) 72 (24%)
Head and neck cancer 99 (31%) 86 (28%)
Lymphoma 75 (23%) 75 (25%)
 High grade non-
Hodgkin lymphoma
47 (15%) 47 (15%)
 Low grade non-
Hodgkin lymphoma
20 (63%) 20 (66%)
Hodgkin lymphoma 8 (3%) 8 (3%)
Tumour stage
Stage I 106 (35%) 104 (36%)
Stage II 73 (24%) 70 (24%)
Stage III 61 (20%) 67 (23%)
Stage IV 64 (21%) 52 (18%)
Missing 16 (5%) 12 (4%)
Treatment
None or single 
treatment
137 (43%) 124 (41%)




249 (78%) 229 (75%)
Multiple comorbidities 71 (22%) 76 (25%)
Time since diagnosis, 
months
25·0 (16·0–41·0) 29·0 (16·5–41·0)
3–<12 39 (12%) 38 (13%)
12–<24 104 (33%) 85 (28%)
24–60 177 (55%) 182 (60%)
Data are mean (SD), n (%), or median (IQR).
Table 1: Baseline characteristics
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different between the intervention group and control 
group over time. No effects on symptoms were found 
among breast cancer survivors (details can be found in 
table 3). For post-hoc analyses of effect sizes at each follow-
up assessment for significant outcomes, see appendix p 4.
The first 1491 survivors (as prespecified in the 
protocol) were invited to complete a survey, of whom 
655 (44%) responded. Respondents were older 
(65·6 years vs 64·2 years, p=0·028) and had a shorter 
time since diagnosis (27·9 months vs 30·1 months, 
Baseline 1 week 
post-intervention
3-month follow-up 6-month follow-up Linear mixed-model 
analysis (p value)
n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) Difference (95% CI)
Intervention 320 ·· 264 ·· 231 ·· 225 ·· ·· ··
Control 305 ·· 275 ·· 261 ·· 251 ·· ·· ··
Patient activation
Total score, patient activation measure
Intervention 292 59·2 (12·5) 245 57·2 (12·2) 217 59·5 (12·7) 209 60·0 (13·7) 1·7 (−0·8 to 4·2) 0·41
Control 277 59·5 (12·6) 251 56·9 (11·4) 241 57·9 (12·5) 234 58·3 (12·7) ·· ··
HRQOL
Summary score QLQ-C30
Intervention 320 85·3 (14·9) 259 88·4 (12·1) 228 88·7 (13·2) 223 89·3 (12·3) 2·3 (0·0 to 4·5) 0·048
Control 304 85·4 (13·6) 271 86·2 (12·8) 253 86·5 (13·1) 247 87·0 (12·7) ·· ··
Mental adjustment to cancer
Summary positive adjustment*
Intervention 319 48·8 (6·1) 259 47·8 (6·3) 228 47·9 (6·5) 223 47·8 (7·1) 0·5 (−0·7 to1·8) 0·77
Control 304 47·6 (6·8) 271 47·3 (6·9) 253 47·1 (6·8) 247 47·3 (6·6) ·· ··
Summary negative adjustment
Intervention 320 28·2 (7·0) 259 27·8 (6·7) 228 27·3 (6·7) 223 27·2 (6·8) −1·1 (−2·4 to 0·1) 1·00
Control 304 29·0 (7·0) 271 29·1 (7·4) 253 28·5 (7·6) 247 28·4 (7·4) ·· ··
Supportive care needs
Physical and daily living
Intervention 319 22·2 (24·7) 260 18·6 (22·9) 229 17·1 (22·7) 224 17·4 (23·6) −1·1 (−5·3 to 3·1) 0·50
Control 305 22·6 (23·4) 273 20·8 (22·1) 257 20·0 (22·4) 249 18·6 (22·8) ·· ··
Psychological
Intervention 319 24·1 (24·0) 260 18·8 (21·2) 229 16·4 (19·2) 224 15·5 (19·9) −5·2 (−9·1 to 1·3) 0·18
Control 305 25·0 (23·1) 273 22·3 (22·4) 257 21·5 (22·1) 249 20·7 (23·1) ·· ··
Sexuality
Intervention 308 15·7 (25·3) 252 11·9 (22·0) 223 12·3 (23·1) 220 11·3 (21·3) −2·0 (−6·2 to 2·1) 0·35
Control 297 15·9 (26·5) 268 14·6 (24·1) 253 14·6 (24·4) 240 13·4 (23·7) ·· ··
Health system, information and patient support
Intervention 319 20·0 (22·2) 260 14·8 (19·0) 229 12·2 (17·0) 223 12·6 (18·3) −1·0 (−4·3 to 2.4) 0·41
Control 305 20·4 (21·9) 272 17·1 (19·7) 254 15·0 (18·7) 248 13·5 (18·7) ·· ··
Self-efficacy
Total score, general self-efficacy scale
Intervention 320 32·1 (5·2) 263 32·1 (4·8) 229 32·1 (5·0) 224 32·0 (5·1) 0·5 (−0·4 to 1·4) 0·31
Control 305 31·6 (5·0) 274 31·0 (4·6) 259 31·2 (4·9) 250 31·5 (4·6) ·· ··
Personal control
Total score, Pearlin and Schooler mastery scale
Intervention 320 24·3 (4·8) 262 24·6 (4·1) 229 24·6 (4·6) 224 24·5 (4·7) 0·9 (0·0 to 1·7) 0·68
Control 305 24·0 (5·2) 273 23·7 (4·5) 258 23·8 (4·7) 250 23·6 (4·8) ·· ··
Perceived efficacy in patient-physician interaction
Total score, perceived efficacy patient–physician interactions scale
Intervention 320 20·8 (3·5) 262 20·5 (3·3) 229 20·6 (3·3) 224 21·0 (3·1) 0·4 (−0·1 to 0·9) 0·22
Control 305 20·8 (3·1) 273 20·4 (3·0) 258 20·7 (3·0) 249 20·6 (2·9) ·· ··
HRQOL=health-related quality of life. QLQ-C30=quality of life questionnaire core 30 items. *The difference between the intervention and control group at baseline was 
statistically different.
Table 2: Mean scores per group per assessment and results of linear mixed-model analyses on the primary and secondary outcomes for the total group
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Baseline 1 week 
post-intervention
3-month follow-up 6-month follow-up Linear mixed-model 
analysis (p value)
n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) Difference (95% CI)
Head and neck cancer, EORTC QLQ-H&N43
Fear of progression
Intervention 99 15·3 (21·9) 82 12·0 (17·2) 68 8·6 (14·3) 68 9·6 (18·5) −2·2 (−8·1 to 3·8) 0·51
Control 86 16·7 (20·8) 76 17·1 (20·9) 71 13·8 (18·7) 64 11·7 (15·9) ·· ··
Body image
Intervention 99 9·4 (19·1) 82 9·2 (19·5) 68 6·5 (20·2) 68 7·7 (21·0) −3·3 (−10·3 to 3·7) 0·62
Control 86 12·5 (20·8) 76 13·6 (19·2) 71 11·3 (18·1) 64 10·9 (19·6) ·· ··
Dry mouth and sticky saliva
Intervention 99 35·2 (28·9) 82 35·2 (27·7) 68 31·1 (28·9) 68 26·0 (26·5) −3·4 (−12·6 to 5·7) 0·48
Control 86 32·9 (28·5) 76 36·6 (31·5) 71 31·7 (29·2) 64 29·4 (26·7) ·· ··
Pain in the mouth
Intervention 99 14·1 (16·0) 82 14·1 (17·6) 68 9·6 (14·8) 68 7·0 (10·7) −8·6 (−14·2 to 3·1) 0·010
Control 86 14·5 (18·1) 76 16·8 (18·2) 71 15·7 (18·6) 64 15·6 (19·9) ·· ··
Sexuality
Intervention 83 20·7 (30·4) 70 19·0 (27·7) 60 14·7 (27·3) 58 13·8 (26·5) −10·7 (−22·8 to 1·4) 0·11
Control 73 25·1 (34·4) 66 30·1 (34·6) 57 24·9 (32·8) 49 24·5 (35·0) ·· ··
Problems with senses
Intervention 99 19·0 (26·5) 82 18·5 (25·7) 68 12·0 (19·7) 68 13·5 (22·0) −2·7 (−11·2 to 5·9) 0·36
Control 86 17·4 (25·8) 76 17·3 (26·9) 71 16·7 (25·4) 64 16·1 (27·5) ·· ··
Problems with shoulder
Intervention 99 10·3 (20·3) 82 11·2 (19·3) 68 8·6 (18·5) 68 10·3 (20·6) −3·0 (−10·6 to 4·6) 0·82
Control 86 10·7 (19·8) 76 11·2 (20·6) 71 12·2 (22·4) 64 13·3 (23·6) ·· ··
Skin problems
Intervention 99 10·5 (14·7) 82 8·7 (15·7) 68 4·2 (7·4) 68 6·0 (13·6) −0·6 (−5·4 to 4·2) 0·51
Control 86 9·0 (17·3) 76 9·1 (15·1) 71 6·6 (11·7) 64 6·6 (14·2) ·· ··
Social eating
Intervention 99 16·3 (27·0) 82 15·8 (24·6) 68 10·7 (24·2) 68 7·6 (17·8) −9·6 (−18·2 to 1·0) 0·038
Control 86 16·3 (25·9) 76 18·3 (27·6) 71 17·5 (29·2) 64 17·2 (30·0) ·· ··
Speech
Intervention 99 16·0 (23·9) 82 15·1 (25·5) 68 10·9 (22·4) 68 8·5 (15·4) −6·9 (−13·0 to −0·8) 0·19
Control 86 15·0 (19·8) 76 19·4 (23·1) 71 16·0 (20·7) 64 15·4 (19·9) ·· ··
Swallowing
Intervention 99 15·3 (23·1) 82 13·3 (21·0) 68 10·8 (21·3) 68 7·0 (12·7) −6·2 (−12·5 to 0·2) 0·045
Control 86 14·1 (22·4) 76 15·9 (24·0) 71 14·4 (22·8) 64 13·2 (22·4) ·· ··
Problems with teeth
Intervention 99 12·8 (20·0) 82 11·0 (17·2) 68 8·2 (14·7) 68 8·5 (14·1) −5·0 (−12·4 to 2·3) 0·29
Control 86 15·0 (26·4) 76 14·6 (23·9) 71 14·6 (23·2) 64 13·5 (26·1) ·· ··
Coughing
Intervention 99 13·8 (24·7) 82 13·8 (21·6) 68 10·3 (19·3) 68 6·9 (15·8) −7·2 (−14·2 to −0·2) 0·017
Control 86 11·2 (20·8) 76 17·5 (28·0) 71 16·4 (25·7) 64 14·1 (23·6) ·· ··
Swelling in the neck
Intervention 99 5·4 (14·8) 82 6·9 (20·1) 68 5·4 (18·8) 68 2·9 (11·1) 1·4 (−1·9 to 4·6) 0·97
Control 86 4·7 (15·5) 76 6·1 (17·0) 71 3·8 (13·3) 64 1·6 (7·1) ·· ··
Neurological problems
Intervention 99 12·8 (24·6) 82 14·6 (25·2) 68 11·3 (21·2) 68 8·3 (17·6) −6·8 (−14·9 to 1·3) 0·24
Control 86 16·7 (29·3) 76 15·8 (28·0) 71 12·7 (24·1) 64 15·1 (27·8) ·· ··
Trismus
Intervention 99 14·8 (27·4) 82 15·9 (27·3) 68 10·3 (22·5) 68 7·8 (20·9) −11·9 (−21·5 to −2·4) 0·046
Control 86 16·7 (29·7) 76 18·0 (30·0) 71 19·7 (31·7) 64 19·8 (32·9) ·· ··
(Table 3 continues on next page)
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Baseline 1 week 
post-intervention
3-month follow-up 6-month follow-up Linear mixed-model 
analysis (p value)
n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) Difference (95% CI)
(Continued from previous page)
Social contact
Intervention 99 2·7 (10·3) 82 2·0 (9·6) 68 1·5 (6·9) 68 1·0 (5·7) −3·7 (−8·1 to 0·7) 0·92
Control 86 5·4 (16·9) 76 6·6 (20·4) 71 6·1 (18·9) 64 4·7 (16·7) ·· ··
Weight loss
Intervention 99 10·8 (24·7) 82 7·3 (18·9) 68 3·9 (15·8) 68 2·9 (13·8) −1·7 (−7·0 to 3·5) 0·48
Control 86 9·7 (25·0) 76 9·6 (24·2) 71 7·0 (22·5) 64 4·7 (16·7) ·· ··
Problems with wound healing
Intervention 99 6·7 (19·0) 82 3·3 (11·2) 68 3·9 (15·8) 68 1·0 (5·7) −1·1 (−4·5 to 2·3) 0·12
Control 86 5·0 (17·4) 76 5·7 (16·7) 71 0·9 (7·9) 64 2·1 (13·1) ·· ··
Colorectal cancer, EORTC QLQ-CR29
Urinary frequency
Intervention 80 27·3 (22·5) 67 20·6 (21·7) 59 27·4 (24·1) 61 21·3 (20·7) −6·2 (−13·4 to 1·1) 0·39
Control 72 31·7 (23·4) 63 27·8 (20·3) 63 27·8 (21·0) 60 27·5 (19·6) ·· ··
Blood and mucus in stool
Intervention 80 1·7 (6·3) 67 1·0 (4·9) 59 1·4 (5·6) 61 1·1 (4·2) −2·0 (−4·5 to 0·6) 0·47
Control 72 2·1 (7·4) 63 2·9 (11·0) 63 1·9 (6·8) 60 3·1 (8·9) ·· ··
Stool frequency
Intervention 80 17·1 (22·0) 67 12·4 (17·0) 59 14·4 (19·4) 61 12·0 (17·8) −6·6 (−13·4 to 0·2) 0·56
Control 71 19·2 (20·4) 63 18·3 (19·8) 63 19·8 (21·1) 60 18·6 (20·1) ·· ··
Body image
Intervention 80 10·1 (15·5) 67 8·6 (13·2) 59 8·3 (13·9) 61 8·2 (12·3) −8·5 (−14·7 to −2.2) 0·53
Control 72 15·9 (22·1) 63 17·1 (21·7) 63 16·6 (19·7) 60 16·7 (21·3) ·· ··
Urinary incontinence
Intervention 80 10·8 (18·2) 67 9·0 (18·0) 59 10·7 (19·0) 61 12·6 (23·7) 8·2 (1·4 to 14·8) 0·18
Control 72 4·2 (11·1) 63 5·8 (14·1) 63 4·2 (11·2) 60 4·4 (11·4) ·· ··
Dysuria
Intervention 80 0·8 (5·2) 67 0 59 2·3 (8·5) 61 1·1 (8·5) 0·0 (−2·7 to 2·6) 0·32
Control 72 0·5 (3·9) 63 1·1 (5·9) 63 1·1 (5·9) 60 1·1 (6·0) ·· ··
Abdominal pain
Intervention 80 10·8 (20·4) 67 10·0 (20·9) 59 13·0 (21·5) 61 5·5 (16·3) −6·2 (−13·3 to 0·9) 0·064
Control 72 10·2 (21·4) 63 8·5 (15·8) 63 13·2 (25·1) 60 11·7 (22·8) ·· ··
Buttock pain
Intervention 80 10·4 (19·6) 67 10·4 (22·6) 59 9·0 (20·4) 61 8·2 (20·8) −0·1 (−7·0 to 6·7) 0·64
Control 72 8·3 (21·5) 63 7·4 (15·2) 63 7·9 (19·6) 60 8·3 (16·9) ·· ··
Bloating
Intervention 80 16·3 (24·3) 67 10·0 (21·7) 59 10·7 (21·8) 61 10·4 (18·8) −2·4 (−9·6 to 4·8) 0·12
Control 72 13·4 (19·9) 63 14·3 (20·5) 63 16·4 (26·0) 60 12·8 (21·3) ·· ··
Dry mouth
Intervention 80 12·5 (22·1) 67 14·9 (24·8) 59 14·1 (24·9) 61 14·8 (24·0) −0·8 (−8·7 to 7·1) 0·97
Control 72 12·5 (20·5) 63 13·8 (20·4) 63 13·8 (19·5) 60 15·6 (19·9) ·· ··
Hair loss
Intervention 80 1·3 (6·4) 67 0·5 (4·1) 59 1·1 (6·1) 61 0 −2·8 (−6·4 to 0·9) 0·060
Control 72 0·5 (3·9) 63 2·6 (10·9) 63 0·5 (4·2) 60 2·8 (14·1) ·· ··
Taste
Intervention 80 2·5 (12·7) 67 2·0 (9·8) 59 1·7 (9·6) 61 1·1 (6·0) −2·8 (−7·0 to 1·4) 0·92
Control 72 6·5 (19·9) 63 5·8 (17·5) 63 5·8 (17·5) 60 3·9 (15·1) ·· ··
Anxiety
Intervention 80 13·3 (18·8) 67 14·4 (18·6) 59 14·7 (19·8) 61 11·5 (18·1) −8·5 (−16·2 to −0·9) 0·80
Control 72 19·0 (22·9) 63 19·6 (22·9) 63 19·0 (20·5) 60 20·0 (23·9) ·· ··
(Table 3 continues on next page)
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Baseline 1 week 
post-intervention
3-month follow-up 6-month follow-up Linear mixed-model 
analysis (p value)
n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) Difference (95% CI)
(Continued from previous page)
Weight
Intervention 80 15·4 (22·5) 67 14·4 (21·9) 59 12·4 (18·5) 61 10·4 (17·8) −10·7 (−18·1 to −3·3) 0·028
Control 72 20·4 (27·2) 63 19·6 (22·1) 63 21·2 (21·8) 60 21·1 (22·9) ·· ··
Flatulence
Intervention 80 31·7 (31·3) 67 27·9 (28·8) 59 26·6 (27·5) 61 25·1 (27·7) −7·1 (−17·0 to 2·8) 0·13
Control 71 29·6 (23·6) 63 29·6 (20·8) 63 33·3 (27·4) 60 32·2 (27·4) ·· ··
Faecal incontinence
Intervention 80 8·8 (21·0) 67 8·0 (19·3) 59 9·0 (19·4) 61 6·0 (14·3) −2·9 (−8·6 to 2·8) 0·49
Control 71 8·0 (19·1) 63 10·6 (17·8) 63 11·1 (19·9) 60 8·9 (17·2) ·· ··
Sore skin
Intervention 80 12·9 (24·0) 67 10·9 (21·2) 59 9·6 (20·6) 61 7·7 (19·6) −1·8 (−8·3 to 4·7) 0·24
Control 71 8·5 (20·9) 63 12·7 (21·1) 63 9·5 (21·9) 60 9·4 (16·3) ·· ··
Embarrassment
Intervention 80 16·3 (27·0) 67 15·4 (27·4) 59 15·8 (25·8) 61 12·0 (22·8) −4·6 (−13·5 to 4·2) 0·65
Control 71 16·9 (28·7) 63 17·5 (26·7) 63 19·6 (26·5) 60 16·7 (26·4) ·· ··
Stoma care problems
Intervention 10 10·0 (31·6) 10 10·0 (22·5) 8 0 7 0 −2·8 (−10·5 to 5·0) 0·30
Control 14 0 13 5·1 (18·5) 14 2·4 (8·9) 12 2·8 (9·6) ·· ··
Sexual interest (men)
Intervention 45 42·2 (27·0) 41 44·7 (24·3) 35 42·9 (23·7) 34 49·0 (22·1) 0·1 (−10·3 to 10·5) 0·76
Control 46 44·2 (24·4) 47 46·8 (27·5) 48 47·2 (23·7) 47 48·9 (23·9) ·· ··
Impotence (men)
Intervention 45 46·7 (38·5) 37 45·0 (36·2) 35 38·1 (38·0) 34 45·1 (36·6) 1·4 (−14·7 to 17·5) 0·76
Control 46 37·0 (38·6) 44 41·7 (36·7) 47 42·6 (39·1) 45 43·7 (34·7) ·· ··
Sexual interest (women)
Intervention 23 27·5 (23·9) 19 29·8 (21·9) 15 35·6 (19·8) 19 29·8 (21·9) 3·9 (−12·7 to 20·5) 0·49
Control 11 21·2 (16·8) 10 16·7 (17·6) 11 27·3 (20·1) 9 25·9 (14·7) ·· ··
Dyspareunia (women)
Intervention 23 5·8 (16·4) 15 15·6 (24·8) 15 2·2 (8·6) 18 1·9 (7·9) −5·6 (17·2 to 6·1) 0·26
Control 9 3·7 (11·1) 6 11·1 (17·2) 12 5·6 (13·0) 9 7·4 (14·7) ·· ··
Lymphoma (high grade non-Hodgkin), EORTC QLQ-NHL-HG29
Symptom burden
Intervention 47 15·2 (17·0) 35 15·2 (18·8) 36 13·5 (19·2) 33 12·7 (17·8) 0·7 (−7·3 to 8·6) 0·33
Control 47 15·3 (16·0) 43 11·8 (11·3) 34 13·7 (19·3) 38 12·0 (15·7) ·· ··
Neuropathy
Intervention 47 23·4 (26·8) 35 22·9 (28·9) 36 22·7 (26·2) 33 16·7 (25·0) −2·6 (−15·4 to 10·2) 0·30
Control 47 17·4 (25·3) 43 17·1 (23·7) 34 17·6 (28·1) 38 19·3 (28·6) ·· ··
Physical condition/fatigue
Intervention 47 20·1 (23·4) 35 15·2 (19·2) 36 17·2 (24·1) 33 15·2 (22·2) −4·0 (−14·3 to 6·4) 0·97
Control 47 19·6 (18·7) 43 16·0 (16·7) 34 17·6 (20·9) 38 19·1 (21·4) ·· ··
Emotional impacts
Intervention 47 16·7 (21·2) 35 14·8 (19·0) 36 17·1 (23·1) 33 12·1 (17·9) −3·2 (−12·4 to 6·0) 0·049
Control 47 20·6 (22·2) 43 17·2 (20·6) 34 13·7 (20·3) 38 15·4 (20·6) ·· ··
Worries/fears about health and functioning
Intervention 47 19·0 (16·7) 35 17·3 (17·7) 36 16·1 (16·3) 33 13·9 (16·1) −2·6 (−12·0 to 6·7) 0·75
Control 46 17·8 (19·8) 43 15·7 (18·7) 34 18·2 (25·0) 38 16·6 (22·2) ·· ··
(Table 3 continues on next page)
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p=0·009) than non-respondents. There were no differ-
ences regarding sex, tumour type, or tumour stage. 
Of the 655 respondents, 211 (32%) were not eligible for 
participation. Multivariable regression analyses showed 
that male sex (odds ratio [OR] 0·48, 95% CI 0·26–0·88), 
younger age (0·94, 0·92–0·97), higher health literacy 
(2·68, 1·75–4·10), higher positive adjustment (1·05, 
1·02–1·09), and lower unmet supportive care needs 
regarding health system information and supportive 
care (0·57, 0·35–0·93) were significantly associated 
with eligibility; also, survivors of colorectal cancer 
(2·42, 1·27–4·63), breast cancer (2·84, 1·37–5·92), 
Hodgkin lymphoma, or non-Hodgkin lymphoma 
(3·50, 1·42–8·59) were more likely to be eligible than 
were head and neck cancer survivors. The other 
measured sociodemographic, clinical, and psychosocial 
characteristics were not significantly associated with 
eligibility.
Of the 444 eligible survivors invited to participate in 
the first recruitment phase, 201 (45%) agreed (the reach). 
Multi variable regression analyses showed that higher 
education (medium vs low OR 1·90, 95% CI 1·16–3·09), 
unmet supportive care needs for sexual problems 
(1·64, 1·02–2·63), and a higher belief of control of 
health by powerful others (ie, medical specialists; 
1·06, 1·02–1·11) were significantly associated with 
participation in the trial. The other measured socio-
demographic, clinical, and psychosocial characteristics 
were not significantly associated with participation. 
After the first recruitment phase with sufficient 
respondents to evaluate the reach (n=655), survivors 
were invited directly to participate in the randomised 
controlled trial.
Within the intervention group, 248 (78%) of the 
320 survivors activated their account, and 167 (52%) used 
Oncokompas as intended at least once during the 
6-month follow-up period. Among intended users, the 
mean number of logins was 3·84 (SD 2·86). Post-hoc 
multi variable regression analyses showed that higher 
education (high vs low 95% CI 2·24, 1·26–3·96), having 
a partner (1·98, 1·07–3·66), and not being employed 
(0·56, 0·35–0·91) were significantly associated with 
Baseline 1 week 
post-intervention
3-month follow-up 6-month follow-up Linear mixed-model 
analysis (p value)
n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) Difference (95% CI)
(Continued from previous page)
Breast cancer, EORTC QLQ-BR23
Body image
Intervention 66 80·6 (26·9) 55 87·4 (19·6) 45 88·7 (16·5) 45 88·7 (18·6) 0·1 (−7·2 to 7·4) 0·43
Control 72 83·3 (22·6) 65 85·5 (21·9) 62 88·3 (18·1) 62 88·6 (18·9) ·· ··
Sexual functioning
Intervention 62 23·4 (21·2) 47 25·2 (20·8) 39 23·9 (21·9) 38 24·6 (18·1) −2·6 (−11·1 to 5·8) 0·76
Control 62 23·1 (21·6) 57 24·9 (20·7) 53 25·8 (19·2) 49 27·2 (20·9) ·· ··
Sexual enjoyment
Intervention 35 52·4 (28·3) 28 50·0 (23·1) 22 56·1 (26·0) 24 56·9 (23·0) −0·3 (−14·1 to 13·4) 0·98
Control 35 57·1 (27·5) 37 55·0 (25·1) 36 57·4 (27·2) 32 57·3 (27·1) ·· ··
Future perspective
Intervention 66 68·7 (27·3) 55 75·2 (23·3) 45 74·8 (20·3) 45 77·8 (23·6) 5·2 (−4·5 to 14·9) 0·40
Control 72 70·4 (26·0) 65 75·9 (25·4) 62 71·0 (26·6) 62 72·6 (26·0) ·· ··
Systemic therapy side-effects
Intervention 66 16·5 (14·1) 55 13·1 (12·3) 45 12·4 (10·8) 45 15·3 (13·7) 0·1 (−4·9 to 5·0) 0·87
Control 71 16·0 (12·3) 65 15·0 (12·2) 62 14·8 (11·0) 62 15·3 (11·9) ·· ··
Breast symptoms
Intervention 66 17·7 (18·2) 55 16·4 (17·7) 45 14·3 (14·2) 45 14·1 (13·0) −1·0 (−7·4 to 5·4) 0·44
Control 72 18·2 (19·6) 65 16·8 (18·5) 62 19·0 (19·6) 62 15·1 (18·5) ·· ··
Arm symptoms
Intervention 66 19·5 (18·4) 55 18·2 (18·9) 45 18·5 (16·6) 45 16·3 (17·7) 0·5 (−6·9 to 7·9) 0·53
Control 72 16·7 (18·6) 65 17·1 (18·5) 62 18·1 (18·0) 62 15·8 (19·8) ·· ··
Upset by hair loss
Intervention 14 38·1 (38·9) 9 18·5 (24·2) 10 16·7 (23·6) 14 16·7 (28·5) −3·3 (−21·0 to 15·0) 0·31
Control 16 16·7 (21·1) 12 13·9 (17·2) 13 17·9 (17·3) 15 20·0 (16·9) ·· ··
Owing to the small numbers of low-grade non-Hodgkin lymphoma and Hodgkin lymphoma survivors, the linear mixed models analyses were not performed on tumour-
specific symptoms for these two types of lymphoma. EORTC=European Organisation for Research and Treatment of Cancer. QLQ=quality of life questionnaire. H&N43=head 
and neck 43 items. CR29=colorectal cancer 29 items. NHL-HG29=non-Hodgkin lymphoma, high grade, 29 items. BR23=breast cancer 23 items.
Table 3: Mean scores per group per assessment and results of linear mixed-model analyses on tumour-specific symptoms
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usage of Oncokompas as intended. The other 
measured sociodemographic, and clinical, psychosocial, 
and internet-related factors were not significantly 
associated with usage.
Discussion
In this randomised controlled trial, we investigated 
whether the fully automated behavioural intervention 
technology Oncokompass could support cancer survivors 
in self-management. There was no significant effect on 
the patients’ amount of knowledge, skills, and confidence 
for self-management (patient activation), the primary 
outcome measure, or the secondary outcome measures 
mental adjustment to cancer, supportive care needs, self-
efficacy, personal control, or perceived efficacy in the 
patient-physician interaction. Oncokompas did improve 
secondary outcome measures of HRQOL and tumour-
specific symptom burden.
Regarding patient activation, the results did not 
confirm the findings from a pilot study on Oncokompas 
among breast cancer survivors, with a pre-test–post-test 
design, in which an increase of patient activation was 
found after use of Oncokompas.11 This might be explained 
by the study design (with a pre–post-test design, 
participants are not randomised), or the fact that the time 
since diagnosis was longer in our randomised controlled 
trial than the pilot study (median of 27 months vs 
12 months in the pilot study), and baseline scores of 
patient activation were higher than they were in the pilot 
study (mean patient activation measure score of 59·3 in 
our randomised controlled trial vs 55·8 in the pilot 
study). Since 57% of the randomised controlled trial 
partici pants were long-term survivors (ie, more than 
2 years after cancer diagnosis), it is possible that 
they had already obtained sufficient knowledge, skills, 
and confidence regarding self-management. Offering 
Oncokompas at an earlier timepoint might therefore be 
beneficial.
The study population in the randomised trial already 
performed relatively well (mean scores in the better range 
of the scales) on most outcome measures when measured 








































































































































Figure 2: The course of different measures over time
(A) HRQOL summary score (a higher score indicates better HRQOL). (B) Trismus in head and neck cancer survivors (a higher score indicates higher symptom burden). 
(C) Worries about weight in colorectal cancer survivors (a higher score indicates higher symptom burden). (D) Emotional impact for both groups in high grade 
non-Hodgkin lymphoma survivors (a higher score indicates higher symptom burden). HRQOL=health-related quality of life. QLQ=quality of life questionnaire. 
C30=core 30 items. H&N43=head and neck 43 items. CR29=colorectal cancer 29 items. NHL-HG29=non-Hodgkin lymphoma, high grade, 29 items.
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outcomes HRQOL and several tumour-specific symptoms 
was better for survivors in the intervention group 
compared with the control group, albeit that the effect 
sizes were small. Some effects were found directly post-
intervention, and sustained over time (eg, HRQOL), 
suggesting that providing survivors with tailored 
information and advice might only improve HRQOL 
soon after cancer survivors start using the application. 
Conversely, effects also occurred at 3 months or 6 months 
follow-up (eg, social eating in head and neck cancer 
survivors). However, it should be noted that this study 
was not powered to detect a difference in secondary 
outcomes such as HRQOL, so these results should be 
interpreted with caution. It might be that survivors need 
time to follow-up on the advice provided and use 
supportive care options and inter ventions offered through 
Oncokompas to improve symptoms. It could also be the 
case that survivors returned to Oncokompas during the 
follow-up period, and that they chose other topics than 
the previous time they completed Oncokompas, so that 
they recieved new information and advice. In practice, 
repeated use of behavioural intervention technologies 
such as Oncokompas is recommended, so that users can 
monitor their scores over time, and compare them with 
previous sessions. This will allow users to monitor 
whether symptoms are improving or when new 
symptoms arise, so that they receive tailored information 
to their current health status and preferences.
Supporting survivors to maintain or improve HRQOL 
and minimise symptom burden after treatment is 
important, but it is difficult to optimally organise long-
term cancer survivorship care.2 This study shows that a 
fully automated behavioural intervention technology 
such as Oncokompas that helps to support survivors 
can potentially improve HRQOL and reduce symptom 
burden. Most effects were found in head and neck 
cancer, several in colorectal cancer and non-Hodgkin 
lymphoma, but no effects were found in breast cancer. 
This might be explained by the differences in the effect 
of the cancer itself and the treatment, but also the 
availability of online information and supportive care 
between various tumour types.
The advantage of fully automated behavioural inter-
vention technologies is that they can be used at any time 
and place, and information and content can be tailored to 
users’ specific needs and preferences, as was applied in 
Oncokompas. A 2019 study of long-term prostate cancer 
survivors also showed that a self-management inter-
vention with personally tailored information is 
promising, especially when tailored to the symptom area 
of choice.7
The results of this study should be considered with 
caution, because of some limitations. The study was 
done in the Netherlands, and the Dutch health-care 
system and percentage of households with internet 
access might not be representative for other countries. 
Another limitation of this study is that a p value of less 
than 0·05 was considered as significant, for both primary 
and secondary outcomes, and that we have tested many 
secondary outcomes, including HRQOL and tumour-
specific symptoms, which might have caused random 
error, and for which the study was not powered. No 
corrections for multiple testing were applied because the 
analyses on secondary outcomes were exploratory, 
because Oncokompas is a complex intervention with 
various cancer-generic and tumour-specific topics in 
multiple HRQOL domains, which leads to several 
conceptually different hypotheses and statistical tests. 
Attrition was higher in the intervention group than in the 
control group, which might have affected the results. 
Since 52% of survivors in the intervention group used 
Oncokompas as intended, further qualitative research 
and use of system data is needed to understand the way 
users interact with the system and content of 
Oncokompas, and how this might influence efficacy. The 
effect size on HRQOL was small and possibly not 
clinically relevant (mean difference between groups was 
less than 10 points on a 100-point scale). In the stratified 
analyses per tumour type, effect sizes on tumour-specific 
symptoms varied from moderate to large, and only the 
difference on trismus in head and neck cancer survivors, 
and weight in colorectal cancer survivors, was clinically 
relevant (difference of >10 points). Another limitation is 
that participants had relatively few comorbidities, were 
often long-term survivors of early stage cancer, and were 
doing relatively well with respect to most outcome 
measures. Although it is important to know that this well 
performing population of cancer survivors still benefitted 
from Oncokompas, further qualitative research is needed 
into the reasons some survivors were not reached.
A strength of this study is the large sample size, with 
survivors from 14 hospitals, and that we included 
survivors with both more prevalent (breast cancer and 
colorectal cancer) and less prevalent tumour types (head 
and neck cancer, Hodgkin lymphoma and non-Hodgkin 
lymphoma), both men and women, and survivors from 
3 months up to 5 years after treatment. Another strength 
is that we investigated the eligibility for eHealth in 
general (estimated at 68%) and the reach of a fully 
automated behavioural intervention tech nology such as 
Oncokompas in particular (estimated at 45% of eligible 
survivors), and also the usage of Oncokompas as 
intended (estimated at 52%), which were associated with 
several socio demographic, clinical, and psychosocial 
factors. These findings contri bute to developing tailored 
strategies for development and implementation of 
eHealth appli cations for cancer survivors. As positive 
effects were found on tumour-specific symptoms, 
developing more tumour-specific modules could be 
explored in future. Another strength is that Oncokompas 
is a self-management application that survivors can use 
independently of their health-care provider, in contrast to 
previous studies,5 which might facilitate sustainability of 
long-term survivorship care. Further research will 
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provide insight into whether Oncokompas is cost-
effective compared with usual survivorship care. Further 
qualitative research and process evaluations are needed 
to guide upscaling of behavioural intervention 
technologies such as Oncokompas. This study also raises 
new questions on which factors contribute to the efficacy 
of a behavioural intervention technology such as 
Oncokompas. We will further investigate engagement 
and the influence of sociodemographic, clinical, and 
psychosocial factors on the efficacy.
In conclusion, Oncokompas did not improve know-
ledge, skills, and confidence for self-management or 
other secondary outcome measures such as supportive 
care needs. Only secondary outcomes of HRQOL and 
tumour-specific symptom burden were improved.
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